E3 Ubiquitin Ligase Cbl-b Activates the P53 Pathway by Targeting Siva1, a Negative Regulator of ARF, in FLT3 Inhibitor-resistant Acute Myeloid Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2016 Oct 25

PMID 27773928

Citations 12

Authors

I-K Park

W Blum

S D Baker

M A Caligiuri

Affiliations

Soon will be listed here.

Citing Articles

Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia.

Ling C, Cao N, Wang H, Wan Y, Liang X, Guo J Int J Gen Med. 2025; 18:459-472.

PMID: 39895829 PMC: 11787778. DOI: 10.2147/IJGM.S502644.

SIVA-1 enhances acquired chemotherapeutic drug resistance of gastric cancer in vivo by regulating the ARF/MDM2/p53 pathway.

Wang X, Li L, Zhu Z, Huang Y, Chen H, Shi Z Heliyon. 2024; 10(2):e24394.

PMID: 38312638 PMC: 10834467. DOI: 10.1016/j.heliyon.2024.e24394.

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.

Shen J, Wang Q, Mao Y, Gao W, Duan S MedComm (2020). 2023; 4(3):e288.

PMID: 37256211 PMC: 10225743. DOI: 10.1002/mco2.288.

Early growth response-1: Key mediators of cell death and novel targets for cardiovascular disease therapy.

Xie Y, Li Y, Chen J, Ding H, Zhang X Front Cardiovasc Med. 2023; 10:1162662.

PMID: 37057102 PMC: 10086247. DOI: 10.3389/fcvm.2023.1162662.

E3 ubiquitin ligases in the acute leukemic signaling pathways.

Zhan Q, Zhang H, Wu B, Zhang N, Zhang L Front Physiol. 2022; 13:1004330.

PMID: 36439256 PMC: 9691902. DOI: 10.3389/fphys.2022.1004330.

References

Van Nostrand J, Brisac A, Mello S, Jacobs S, Luong R, Attardi L . The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development. Cancer Discov. 2015; 5(6):622-35. PMC: 4456277. DOI: 10.1158/2159-8290.CD-14-0921. View

Brown C, Lain S, Verma C, Fersht A, Lane D . Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009; 9(12):862-73. DOI: 10.1038/nrc2763. View

Wang X, Zha M, Zhao X, Jiang P, Du W, Tam A . Siva1 inhibits p53 function by acting as an ARF E3 ubiquitin ligase. Nat Commun. 2013; 4:1551. DOI: 10.1038/ncomms2533. View

Zorko N, Bernot K, Whitman S, Siebenaler R, Ahmed E, Marcucci G . Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood. 2012; 120(5):1130-6. PMC: 3412333. DOI: 10.1182/blood-2012-03-415067. View

Oshikawa G, Nagao T, Wu N, Kurosu T, Miura O . c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. J Biol Chem. 2011; 286(35):30263-30273. PMC: 3162385. DOI: 10.1074/jbc.M111.232348. View

Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin J . FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009; 12(3):81-9. PMC: 4472331. DOI: 10.1016/j.drup.2009.04.001. View

Chen D, Yoon J, Gu W . Reactivating the ARF-p53 axis in AML cells by targeting ULF. Cell Cycle. 2010; 9(15):2946-51. PMC: 3040923. DOI: 10.4161/cc.9.15.12355. View

Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P . SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 2014; 15(4):431-446. PMC: 4305398. DOI: 10.1016/j.stem.2014.08.001. View

Martins C, Brown-Swigart L, Evan G . Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006; 127(7):1323-34. DOI: 10.1016/j.cell.2006.12.007. View

10.

Sasca D, Hahnel P, Szybinski J, Khawaja K, Kriege O, Pante S . SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood. 2014; 124(1):121-33. DOI: 10.1182/blood-2013-11-538819. View

11.

Liyasova M, Ma K, Lipkowitz S . Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment. Clin Cancer Res. 2014; 21(8):1789-94. PMC: 4401614. DOI: 10.1158/1078-0432.CCR-13-2490. View

12.

Sudhindra A, Smith C . FLT3 inhibitors in AML: are we there yet?. Curr Hematol Malig Rep. 2014; 9(2):174-85. DOI: 10.1007/s11899-014-0203-8. View

13.

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

14.

Andreeff M, Kelly K, Yee K, Assouline S, Strair R, Popplewell L . Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2015; 22(4):868-76. PMC: 4809642. DOI: 10.1158/1078-0432.CCR-15-0481. View

15.

Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine J . Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther. 2011; 10(6):983-93. DOI: 10.1158/1535-7163.MCT-10-1090. View

16.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M . The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica. 2012; 97(11):1722-30. PMC: 3487447. DOI: 10.3324/haematol.2012.062083. View